Healthcare Professionals
Compia MRI Quad CRT-D
Cardiac Resynchronization Therapy Defibrillators (CRT-D)
Du har precis klickat på en länk som tar dig till en annan webbplats. Om du fortsätter kommer du att lämna denna webbplats och gå till en webbplats som drivs av någon annan.
Medtronic Sverige varken granskar eller kontrollerar innehållet på den andra webbplatsen och tar inget ansvar för eventuella affärstransaktioner som du utför där. Din användning av den andra webbplatsen är föremål för användarvillkoren och sekretesspolicyn på den webbplatsen.
Det är möjligt att vissa produkter på den andra platsen inte är godkända i Sverige.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Välkommen till vår information för hälso- och sjukvårdspersonal.
Här hittar du produktinformation och annan info framtagen för dig som arbetar inom vården.
Arbetar du inom ett vårdyrke?
Healthcare Professionals
Cardiac Resynchronization Therapy Defibrillators (CRT-D)
Lunati MG, Gasparini M, Landolina M, et al. Long-Term Effect of Steroid Elution on the Electrical Performance of Coronary Sinus Leads for Cardiac Resynchronization Therapy. Presented at HRS 2012 (AB10-05).
Biffi M, et al. Utilizing Short Spacing between Quadripolar LV lead Electrodes to Avoid PNS. Cardiostim 2014, Poster presentation, Session 56P.
Biffi M, Foerster L, Eastman W, et al. Effect of bipolar electrode spacing on phrenic nerve stimulation and left ventricular pacing thresholds: an acute canine study. Circ Arrhythm Electrophysiol. August 1, 2012;5(4):815-820.
Biffi M, Zanon F, Bertaglia E, et al. Short-spaced dipole for managing phrenic nerve stimulation in patients with CRT: the "phrenic nerve mapping and stimulation EP" catheter study. Heart Rhythm. January 2013;10(1):39-45.
Demmer W. VectorExpress Performance Results. Medtronic Data on File, January 2013.
Pressure contour plots are scaled relative to each other, header to header, device body to device body. The device body pressure uses an enhanced scaling to demonstrate the pressure differences across the device body; therefore actual pressure is not relative to the header pressure. Note: Analysis for Evera and Device A dual chamber ICDs with DF-4 connectors were used. Analysis for Device B and C used dual chamber ICDs with DF-1 connectors.
Flo. Daniel IS4/DF4 Device Shape Analysis. January 2013. Medtronic data on file.
Ceelen KK. et al. J Biomech. 2008;41:3399-3404.
Sowell LV. et al. J Women's Health. 2006;15:830-835.
Gold MR. et al. J Am Coll Cardiol. 1996;28:1278-1282.
Kolker AR. et al. Ann Plastt Surg. 2007;59:26-30.
Kadish A. et al. Circulation. 2005;111:3327-3335.
Shapiro M. et al. Indian Pacing Electrophyesiol J. 2004;4:213-216.
Our performance assurance program demonstrates the confidence we have in SmartShock. We will reimburse up to $500 to any patient with an eligiible device* — one with SmartShock or SmartShock 2.0 Technology — who receives an inappropriate shock, to help cover certain unreimbursed medical expenses incurred while seeking medical care.†
SmartShock is nominally on and clinically proven to reduce shocks1
SmartShock Technology algorithims must be programmed "ON" (with parameter settings below) at the time of the inappropriate shock. Medtronic will cover uninsured medical expense, not to exceed $500, per patient shocked event. This offer is valid for the lifetime of the device.
Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm. May 2015;12(5):926-936.
Identifying Congestion in Patients with Heart Failure
OptiVol® Fluid Status Monitoring tracks intrathoracic impedance changes over time to help clinicians assess congestion in patients with heart failure.*1,2 Heart Failure device diagnostics, with multiple parameters including OptiVol, are proven to identify patients at high risk for heart failure hospitalization.3-5
OptiVol 2.0 enhancements include6:
Reduced Unexplained Detections6
Detail - Unexplained Detections
For CRT-D devices, certain programming and device operations may not provide cardiac resynchronization. Changes in a patient's disease and/or medications may alter the efficacy of a device's programmed parameters.
Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9, 2005;112(6):841-848.
Abraham WT, Compton S, Haas G, et al. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. November 2009;15(9):813.
Small RS, Whellan DJ, Boyle A, et al. Implantable device diagnostics on the day of discharge from a heart failure hospitalization can predict 30 day readmission risk. J Card Fail. August 2012;18(8 Suppl):S50.
Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol. April 27, 2010;55(17):1803-1810.
Whellan DJ, Sarkar S, Koehler J, et al. Development of a method to risk stratify patients with heart failure for 30-day readmission using implantable device diagnostics. Am J Cardio. January 1, 2013;111(1):79-84.
Sarkar S, Hettrick DA, Koehler J, et al. Improved algorithm to detect fluid accumulation via intrathoracic impedance monitoring in heart failure patients with implantable devices. J Card Fail. 2011;17(7):569-576.